Qiyaastii-kansarka / daaweynta / tijaabooyinka-kiliinikada / cudurka / futada-kansarka / daaweynta

Daaweynta Tijaabooyinka Kiliinikada Kansarka

Tijaabooyinka caafimaad waa daraasado cilmi baaris ah oo dadka ku lug leh. Tijaabooyinka caafimaad ee liiskan waxaa loogu talagalay daaweynta kansarka dabada. Dhammaan tijaabooyinka ku jira liiska waxaa taageera NCI.

Macluumaadka aasaasiga ah ee NCI ee ku saabsan tijaabooyinka bukaan socodka wuxuu sharxayaa noocyada iyo wejiyada tijaabooyinka iyo sida loo fuliyo. Tijaabooyinka caafimaad waxay eegaan habab cusub oo looga hortago, lagu ogaado, ama lagu daweeyo cudur. Waxaa laga yaabaa inaad rabto inaad ka fikirto kaqeybqaadashada tijaabada caafimaadka. La hadal dhakhtarkaaga si uu kaaga caawiyo go aansashada haddii mid kugu habboon yahay.

Tijaabada 1-23 ee 23

Nivolumab ka dib Daaweynta Isku-dhafan ee Isku-dhafan ee Daaweynta Bukaannada Heerka Khatarta Sare ee II-IIIB Kansarka Kansarka

Marxaladan tijaabada ah ee tijaabada caafimaad ee wajiga labaad ah ayaa lagu daraaseeyaa sida ugu wanaagsan ee loo yaqaan 'nivolumab' ka dib marka daaweynta isku dhafan ee isku dhafan ay ka shaqeyso daaweynta bukaannada qaba heerka sare ee kansarka dabada II-IIIB. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 744 goobood

Nivolumab leh ama aan lahayn Ipilimumab ee lagu daaweynayo bukaanada qaba kansarka kanaalka ee kansarka 'Metastatic Canal Canal Canal'

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee nivolumab leh ama aan lahayn ipilimumab ay ugu shaqeyso daaweynta bukaanada qaba kansarka kanaalka futada ee aan ka jawaabin daaweyn hore (diidmo) waxayna ku faaftay meelo kale oo jirka ah (metastatic). Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 42 goobood

Nivolumab iyo Ipilimumab ee ku daweynta bukaanada qaba HIV Associated Relapsed ama Refractory Classical Hodgkin Lymphoma ama Burooyinka Adag ee Metastatic ah ama aan lagu saari karin Qalliinka

Tijaabadan wejigan 1aad waxay tijaabisaa dhibaatooyinka soo raaca iyo qiyaasta ugu fiican ee nivolumab markii la siiyo ipilimumab ee lagu daaweynayo bukaanada qaba fayraska difaaca jirka ee aadanaha (HIV) ee laxiriira qanjirka 'Hodgkin lymphoma' ee soo laabtay ka dib muddo horumar ah ama aan ka jawaabin daaweynta, ama burooyinka adag ee ku faafay meelo kale oo jidhka ah ama laguma saari karo qalliin. Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab iyo nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Ipilimumab waa antibody wax ka qabta maaddada loo yaqaan 'cytotoxic T-lymphocyte antigen 4' (CTLA-4). CTLA-4 waxay maamushaa qayb ka mid ah habka difaaca jirka adiga oo xiraya. Nivolumab waa nooc ka mid ah unugyada difaaca jirka ee gaarka u ah geerida unugyada barnaamijka ee bini'aadamka ee loo yaqaan '1' (PD-1), borotiin mas'uul ka ah burburinta unugyada difaaca jirka. Bixinta ipilimumab oo leh nivolumab ayaa si fiican uga shaqeyn karta daaweynta bukaanada qaba HIV-ga la xiriirta hoogkin lymphoma ama burooyinka adag marka la barbar dhigo ipilimumab oo leh nivolumab oo keliya.

Goobta: 28 goobood

Daraasad ku saabsan XmAb®20717 oo ku saabsan Mawduucyo leh Burooyin Adag oo Xul ah

Tani waa Wajiga 1, qaadasho badan, daraasad kordhinta qiyaasta kor u qaadista si loo qeexo MTD / RD iyo nidaamka XmAb20717, si loo sharaxo nabadgelyada iyo dulqaadka, si loo qiimeeyo PK iyo difaaca jirka, iyo in si hordhac ah loo qiimeeyo dhaqdhaqaaqa ka hortagga burooyinka ee XmAb20717 maadooyinka leh xulashada burooyinka adag ee horumarsan.

Goobta: 15 goobood

Daraasad Immuno-therapy ah oo baaritaan ah oo lagu baarayo amniga iyo waxtarka Nivolumab, iyo Nivolumab Isugeynta Daaweynta ee Burooyinka la xiriira Virus

Ujeedada daraasaddan si loo baaro amniga iyo waxtarka nivolumab, iyo daaweynta isku-darka nivolumab, si loo daaweeyo bukaannada qaba burooyinka la xiriira fayraska. Feyrasyada qaarkood ayaa lagu yaqaan inay door ka ciyaaraan sameynta burooyinka iyo koritaanka. Daraasadani waxay baari doontaa saameynta daawooyinka daraasadda, bukaanada leh noocyada burooyinka soo socda: - Cancer Canal Canal-Mar dambe ma diiwaan galiso nooca burooyinka kansarka ilmo galeenka - Epstein Barr Virus (EBV) kansarka caloosha wanaagsan - Mar dambe ma diiwaangelin tan nooca burooyinka - Kansarka Unugyada Kansarka - Kansarka Penile-Mar dambe ma diiwaangeliyo nooca burooyinkaan - Kansarka siilka iyo xubinta taranka-Mar dambe ma diiwaan galinayo nooca burooyinkaan - Kansarka Nasopharyngeal - Mar dambe ma diiwaangelinayo nooca buro - Madaxa iyo Kansarka Qoorta

Goobta: 10 goobood

Daraasada Pembrolizumab (MK-3475) ee Kaqeybgalayaasha leh Burooyinka Soodhawrka Sare leh (MK-3475-158 / KEYNOTE-158)

Daraasaddan, kaqeybgalayaasha leh noocyo kaladuwan oo burooyin adag ah (aan laqeexin karin iyo / ama metastatic) oo kusocday heerka daaweynta caadiga ah waxaa lagu daaweyn doonaa pembrolizumab.

Goobta: 8 goobood

Qiyaasta-Qiyaasta Sare ee Brachytherapy iyo Chemotherapy ee Daaweynta Bukaannada leh Degenaansho soo noqnoqda ama soo noqnoqoshada ama Kansarka Anal ee Lagu Maarayo Maareyn Aan Shaqeyn

Tijaabadan wejigan 1aad waxay daraasad ku samaysaa dhibaatooyinka soo raaca ah iyo qiyaasta ugu fiican ee daaweynta naafada ah ee heerka sare leh marka la siinayo daaweynta kiimikada ee daaweynta bukaannada qaba kansarka malawadka ama dabada oo soo noqday ama ka sii daray oo aan lagu daaweyn karin qalliin. Daaweynta xanuunka loo yaqaan 'Brachytherapy', oo sidoo kale loo yaqaan daaweynta shucaaca gudaha, waxay isticmaashaa walax shucaac ah oo toos loo galiyo ama u dhow buro si loo dilo unugyada burooyinka. Qiyaasta-sare (HDR) brachytherapy waxay isticmaashaa walaxda shucaaca si ay ugu gudbiso qiyaasta shucaaca sare ee muddo gaaban buro. Waxay sidoo kale u diri kartaa shucaac yar unugyada caafimaadka qaba ee u dhow waxayna yareyn kartaa halista waxyeellooyinka. Daawooyinka loo isticmaalo kiimoteraabiga, sida capecitabine iyo fluorouracil, waxay u shaqeeyaan siyaabo kala duwan si ay u joojiyaan koritaanka unugyada burooyinka, iyagoo dilaya unugyada, iyaga oo ka joojinaya kala qaybinta, ama ka joojinta faafitaanka.

Goobta: 6 goobood

Pembrolizumab ee ku daweynta bukaanada kansarka 'Metastatic' ama 'Local Cancer Cancer Cancer' oo aan laga saari karin qalliin

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee pembrolizumab ugu shaqeyso daaweynta bukaanada qaba kansarka dabada kaasoo ku faafay meelo kale oo jirka ah ama ku faafay goobtiisi hore ee koritaanka ilaa unugyada u dhow ama qanjidhada oo aan qalliin looga saari karin. Immunotherapy oo leh unugyada unugyada monoclonal, sida pembrolizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: 5 goobood

Qalliin lagu daaweynayo bukaan socodka marxaladda hore ee Canal Canal ama Cancer Perianal iyo HIV Positive

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa qalliinka lagu daaweynayo bukaanka qaba kanaalka dabada ama kansarka yar yar oo aan si qoto dheer ugu faafin unugyada iyo fayraska difaaca jirka ee aadanaha (HIV). Qalliinka maxalliga ahi wuxuu noqon karaa daaweyn badbaado leh oo leh waxyeelo ka yar qalliinka weyn ama shucaaca iyo kiimoteraabiga.

Goobta: 5 goobood

Tijaabo Lagu Raadinayo laguna Baadhayo Qiyaasta Nabdoon ee Maandooriyaha Cusub (BI 754091) ee loogu talagalay Bukaannada leh Burooyinka Adag

Ujeeddada ugu weyn ee qayb-ka-qaadista ee tijaabada ayaa ah in la go'aamiyo badbaadada iyo dulqaadka, iyo in la go'aamiyo Qiyaasta ugu Adag ee La Xakameeyay iyo / ama Qeybta Lagu Taliyay ee 2 Qiyaasta (RP2D) ee BI 754091 iyadoo lagu saleynayo bukaanada leh xaddid-xaddiga sunta (DLTs) ee bukaanka qaba astaamo adag oo horumarsan. Badbaadada iyo dulqaadka waxaa lagu qiimeyn doonaa iyadoo la kormeerayo dhacdooyinka xun (AEs), AEs daran (SAE), iyo cilladaha xaddiga cabbirka shaybaarka, iyo sidoo kale isbeddelada calaamadaha muhiimka ah. Ujeeddooyinka dugsiga sare waa go'aaminta astaanta PK ee BI 754091 ka dib markii hal iyo dhowr jeer la qaatay BI 754091, iyo qiimeynta hordhaca ah ee dhaqdhaqaaqa antitumour. Qeybta balaadhinta qiyaasta ee tijaabada, ujeedooyinka ugu waaweyn ayaa ah in la sii qiimeeyo amniga, waxtarka, muuqaalka PK,

Goobta: 3 goobood

Qalliinka Stereotactic Radiosur ee Daaweynta Bukaannada qaba Cudurka Oligometastatic

Tijaabadan wejiga II waxay tijaabineysaa sida ugu wanaagsan ee shucaaca qalliinka shucuurta ah uu ugu shaqeeyo daaweynta bukaanada qaba kansarka ku faafay 5 meelood ama in ka yar jirka oo ku lug leh 3 ama in yar oo xubno ah (cudurka oligometastatic). Qalliinka shucaaca 'stereotactic radiosurgery', oo sidoo kale loo yaqaan daaweynta shucaaca jirka ee stereotactic, waa daaweyn shucaac khaas ah oo si toos ah ugu gudbisa hal qadar sare oo shucaac ah burada waxaana laga yaabaa inay disho unugyo badan oo buro ah isla markaana u keento dhaawac yar unugyada caadiga ah.

Goobta: 3 goobood

Daraasad ku saabsan INCMGA00012 ee Kansarka Gawaarida ee Canal Canal Ka Dib Daaweynta Chemotherapy ee Ku-saleysan Platinum (POD1UM-202)

Ujeedada daraasaddan ayaa ah in la qiimeeyo waxtarka INCMGA00012 ee kaqeybgalayaasha leh carcinoma heer sare ah oo heer sare ah ama metastatic ah kanaalka futada (SCAC) kuwaas oo horumar sameeyay ka dib daaweynta kiimikada ku saleysan platina.

Goobta: 4 goobood

Artesunate ee Daaweynta Bukaannada leh Anal Intraepithelial Neoplasia oo Fasal Sare ah

Tijaabadan wejigan 1aad waxay daraasad ku samaysaa dhibaatooyinka soo raaca iyo qiyaasta ugu wanaagsan ee artesunate ee lagu daaweynayo bukaannada qaba futada sare ee finanka 'intraepithelial neoplasia'. Anop intraepithelial neoplasia waa unugyo hordhac ah oo mustaqbalka noqon kara ama noqon kara kansar. Inta badan isbeddelada keena kansarka waxaa sababa Human papillomavirus (HPV). Artesunate waxay dili kartaa unugyada qaba HPV.

Goobta: 2 goobood

Daraasad LY3434172, PD-1 iyo PD-L1 Bispecific Antibody, oo kujira Kansarka Hormarsan

Ujeedada ugu weyn ee daraasaddan ayaa ah in la qiimeeyo amniga iyo dulqaadka daroogada daraasadda LY3434172, oo ah antibiyootiko PD-1 / PD-L1, oo ka qaybgalayaasha leh burooyin adag oo horumarsan.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

SL-279252 (PD1-Fc-OX40L) ee Mawduucyada leh Burooyin Adag oo Horumar leh ama Lymphomas

Tani waa Wajiga 1 ee ugu horreeya bini-aadamka, calaamadda furan, xarumo fara badan, kordhinta qiyaasta iyo daraasadda ballaarinta qiyaasta si loo qiimeeyo amniga, dulqaadka, PK, waxqabadka kahortagga burooyinka iyo saameynta daawooyinka ee SL-279252 maadooyinka leh burooyinka adag ee adag ama lymphomas .

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

LET-IMPT iyo Chemotherapy-ka caadiga ah ee lagu daaweynayo bukaanada qaba marxalada cusub ee la soo ogaadey ee I-III Canal Canal Squamous Cell Cancer

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca ee 'LET-IMPT' iyo daaweynta kiimikada ee caadiga ah, iyo sida wanaagsan ee ay ugu shaqeeyaan daaweynta bukaanada qaba cudurka kansarka unugyada kansarka unugyada kansarka unugyada cusub ee I-III. LET-IMPT waa nooc ka mid ah daaweynta shucaaca ee isticmaasha proton “beamlets” tamarta sare si loogu “rinjiyeeyo” qiyaasta shucaaca ee bartilmaameedka waxayna caawin kartaa in la dilo unugyada burooyinka isla markaana la yareeyo burooyinka. Bixinta LET-IMPT iyo daaweynta kiimiko ee caadiga ah ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba kansarka unugyada kansarka unugyada dabada.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

VGX-3100 iyo Electroporation ee lagu daaweynayo bukaanka qaba nabarrada nabarrada heerka sare ee HIV-ga

Wejigan labaad wuxuu tijaabinayaa sida wanaagsan ee papillomavirus-ka aadanaha (HPV) deoxyribonucleic acid (DNA) plasmids tallaalka daaweynta VGX-3100 (VGX-3100) iyo shaqada elektiroonigga ee lagu daaweynayo bukaanada qaba fayraska difaaca jirka ee aadanaha (HIV) - oo ah heer sare oo dhaawacyo futada ah. Tallaalada laga sameeyay DNA ayaa laga yaabaa inay ka caawiso jirka inuu dhiso jawaab celin wax ku ool ah oo disho unugyada burooyinka. Korantada waxay ka caawisaa daloolada unugyada jirkaaga inay qaataan daawada si loo xoojiyo jawaabta habka difaaca jirka. Siinta VGX-3100 iyo koronto si wadajir ah ayaa laga yaabaa inay si fiican uga shaqeeyaan daaweynta bukaanada qaba nabarrada futada sare leh.

Goobta: 2 goobood

DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Tallaalka Daaweynta INO-3112 iyo Durvalumab ee Daaweynta Bukaannada qaba Kansarrada Soo Noqnoqda ama Metastatic Human Papillomavirus Associated Cancer

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida ugu wanaagsan ee loo yaqaan 'deoxyribonucleic acid' (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids tallaalka daweynta INO-3112 iyo durvalumab waxay ka shaqeeyaan daaweynta bukaanada qaba kansarka papillomavirus ee la xiriira ee soo noqday ama u faafay kuwa kale meelaha jirka. Tallaallada laga sameeyay fayraska hiddo-wadaha wax laga beddelay ayaa laga yaabaa inay ka caawiyaan jirka inuu dhiso jawaab-celin wax-ku-ool ah oo difaac ah si loo dilo unugyada burooyinka. Immunotherapy oo leh unugyada unugyada monoclonal, sida durvalumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Bixinta DNA plasmid-encoding interleukin-12 / HPV DNA plasmids talaalka daaweynta INO-3112 iyo durvalumab ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba kansarka papillomavirus ee la xiriira.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

M7824 ee Mawduucyada leh Xanuunada La Xiriira HPV

Gundhig: Waddanka Mareykanka, sanad walba waxaa kajira in kabadan 30,000 oo kiis oo kansarka la xiriira papillomavirus (HPV). Qaar ka mid ah kansarradan badanaa lama bogsan karo mana ku fiicnaadaan daaweynta caadiga ah. Cilmi-baarayaashu waxay rabaan inay arkaan haddii daawo cusub oo M7824 ah, oo bartilmaameedsata oo xirta waddo ka hortageysa in nidaamka difaaca jirka uu si wax ku ool ah ula dagaallamo kansarka uu yareyn karo burooyinka dadka qaba qaar ka mid ah kansarka HPV. Ujeeddooyinka: Si loo arko haddii daroogada M7824 ay keento burooyinka inay yaraadaan. U qalmida: Dadka qaangaarka ah ee jira 18 ama ka weyn ee qaba kansar la xiriira infekshinka HPV. Naqshad: Kaqeybgalayaasha waxaa laga baari doonaa taariikh caafimaad iyo baaritaan jireed. Waxay dib u eegi doonaan astaamahooda iyo sida ay howlo caadi ah u qabtaan. Waxay heli doonaan baaritaano jirka ah. Waxay kaa qaadi doonaan dhiig iyo kaadi. Waxay qaadan doonaan muunad ka mid ah unugyada burooyinka haddii mid la waayo. Kaqeybgalayaashu waxay yeelan doonaan qalab elektaroonig ah oo lagu qiimeeyo qalbigooda. Kadib waxay ka heli doonaan daroogada daraasadda dhuun khafiif ah oo ku jirta xididka gacanta. Kaqeybgalayaashu waxay dawada heli doonaan 2dii toddobaadba mar 26 jeer (1 sano). Tani waa 1 koorso. Koorsada kadib, kaqeybgalayaasha waa lala socon doonaa laakiin ma qaadan doonaan daroogada daraasadda. Haddii xaaladoodu ka sii darto, waxay ku bilaabi doonaan koorso kale daawada. Nidaamkan waa lagu celin karaa inta jeer ee loo baahdo. Daaweyntu way joogsan doontaa haddii ka-qaybgalaha uu leeyahay waxyeellooyin xun ama daroogadu ay joojiso shaqada. Daraasada oo dhan, kaqeybgalayaashu waxay kucelcelin doonaan qaar ama dhamaan tijaabooyinka baaritaanka. Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... Kadib waxay ka heli doonaan daroogada daraasadda dhuun khafiif ah oo ku jirta xididka gacanta. Kaqeybgalayaashu waxay dawada heli doonaan 2dii toddobaadba mar 26 jeer (1 sano). Tani waa 1 koorso. Koorsada kadib, kaqeybgalayaasha waa lala socon doonaa laakiin ma qaadan doonaan daroogada daraasadda. Haddii xaaladoodu ka sii darto, waxay ku bilaabi doonaan koorso kale daawada. Nidaamkan waa lagu celin karaa inta jeer ee loo baahdo. Daaweyntu way joogsan doontaa haddii ka-qaybgalaha uu leeyahay waxyeellooyin xun ama daroogadu ay joojiso shaqada. Daraasada oo dhan, kaqeybgalayaashu waxay kucelcelin doonaan qaar ama dhamaan imtixaanada baaritaanka. Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... Kadib waxay ka heli doonaan daroogada daraasadda dhuun khafiif ah oo ku jirta xididka gacanta. Kaqeybgalayaashu waxay dawada heli doonaan 2dii toddobaadba mar 26 jeer (1 sano). Tani waa 1 koorso. Koorsada kadib, kaqeybgalayaasha waa lala socon doonaa laakiin ma qaadan doonaan daroogada daraasadda. Haddii xaaladoodu ka sii darto, waxay ku bilaabi doonaan koorso kale daawada. Nidaamkan waa lagu celin karaa inta jeer ee loo baahdo. Daaweyntu way joogsan doontaa haddii ka-qaybgalaha uu leeyahay waxyeellooyin xun ama daroogadu ay joojiso shaqada. Daraasada oo dhan, kaqeybgalayaashu waxay kucelcelin doonaan qaar ama dhamaan imtixaanada baaritaanka. Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... kaqeybgalayaasha waa lala socon doonaa laakiin ma qaadan doonaan daroogada daraasadda. Haddii xaaladoodu ka sii darto, waxay ku bilaabi doonaan koorso kale daawada. Nidaamkan waa lagu celin karaa inta jeer ee loo baahdo. Daaweyntu way joogsan doontaa haddii ka-qaybgalaha uu leeyahay waxyeellooyin xun ama daroogadu ay joojiso shaqada. Daraasada oo dhan, kaqeybgalayaashu waxay kucelcelin doonaan qaar ama dhamaan imtixaanada baaritaanka. Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... kaqeybgalayaasha waa lala socon doonaa laakiin ma qaadan doonaan daroogada daraasadda. Haddii xaaladoodu ka sii darto, waxay ku bilaabi doonaan koorso kale daawada. Nidaamkan waa lagu celin karaa inta jeer ee loo baahdo. Daaweyntu way joogsan doontaa haddii ka-qaybgalaha uu leeyahay waxyeellooyin xun ama daroogadu ay joojiso shaqada. Daraasada oo dhan, kaqeybgalayaashu waxay kucelcelin doonaan qaar ama dhamaan imtixaanada baaritaanka. Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ... Ka-qaybgalayaasha ka dib markay joojiyaan qaadashada daroogada, waxay lahaan doonaan booqasho dabagal ah waxayna ku celin doonaan qaar ka mid ah tijaabooyinka baaritaanka. Waxay heli doonaan wicitaanno taleefan oo soo-noqnoqda. ...

Goobta: Machadyada Qaranka ee Xarunta Caafimaadka, Bethesda, Maryland

MnSOD Mimetic BMX-001 ee lagu daaweynayo bukaanka qaba kansarka dabada ee lagu daweynayo daaweynta shucaaca iyo daaweynta kiimikada

Tijaabadan wejigan 1aad waxay daraaseysaa qiyaasta ugu fiican ee MnSOD mimetic BMX-001 si loo yareeyo dhibaatooyinka soo raaca bukaanka qaba kansarka dabada ee lagu daweynayo shucaaca iyo daaweynta kiimikada. Daawooyinka kiimiko-ilaaliyaha ah, sida BMX-001, ayaa ka ilaalin kara unugyada caadiga ah dhibaatooyinka soo raaca kiimoteraabiga iyadoo la xoojinayo dilka burooyinka.

Goobta: Jaamacadda Nebraska Medical Center, Omaha, Nebraska

Atezolizumab iyo Bevacizumab ee Daaweynta Bukaannada leh Burooyin Adag oo Nadir ah

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee atezolizumab iyo bevacizumab uga shaqeeyaan daaweynta bukaannada qaba burooyinka adag ee dhifka ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida atezolizumab iyo bevacizumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

Daaweynta Talaalka iyo Cyclophosphamide ee lagu daaweynayo bukaanada qaba HLA-A * 02 Positive Relaps, Refractory, or Metastatic HPV16-Oropharyngeal, Cervical, or Canal Cancer

Marxaladani tijaabinta Ib / II waxay daraasad ku samaysaa waxyeelooyinka iyo qiyaasta ugu fiican ee HPV16-E711-19 nanomer tallaalka DPX-E7 iyo in la arko sida wanaagsan ee ay u shaqeyso markii la siinayo cyclophosphamide ee lagu daaweynayo bukaannada qaba HLA-A * 02 positive, human papillomavirus 16 ( HPV16) -laxiriira oropharyngeal, afka ilmo galeenka, ama kansarka dabada oo soo noqday, wax jawaab ah kama bixinaynin daaweynta, ama wuxuu ku faafay qaybaha kale ee jirka. Tallaallada laga sameeyay fayraska hiddo-wadaha wax laga beddelay ayaa laga yaabaa inay ka caawiyaan jirka inuu dhiso jawaab-celin wax-ku-ool ah oo difaac ah si loo dilo unugyada burooyinka. Daawooyinka loo isticmaalo kiimoteraabiga, sida cyclophosphamide, waxay u shaqeeyaan siyaabo kala duwan si ay u joojiyaan koritaanka unugyada burooyinka, iyagoo dilaya unugyada, iyaga oo ka joojinaya inay kala baxaan, ama ka joojiyaan faafitaanka. Siinta HPV16-E711-19 nanomer tallaalka DPX-E7 oo ay weheliso cyclophosphamide waxay si fiican uga shaqeyn kartaa daaweynta bukaanada qaba oropharyngeal ee la xariira HPV16,

Goobta: Dana-Farber Institute Cancer, Boston, Massachusetts

Nivolumab iyo Ipilimumab oo lagu daaweynayo bukaanada leh burooyinka dhifka ah

Wejigan 2aad tijaabinta tijaabada nivolumab iyo ipilimumab ee lagu daaweynayo bukaannada qaba burooyinka dhifka ah. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Tijaabadani waxay uqortaa kaqeybgalayaasha koorsooyinka soo socda oo ku saleysan xaalad: 1. Burooyinka Epithelial ee sanka, sanka, nasopharynx: A) Cudurka unugyada qanjirada 'squamous cell carcinoma' oo leh noocyo sanka sanka ah, sanka, iyo nasopharynx iyo trachea (marka laga reebo laryngeal, kansarka nasopharyngeal [NPC] , iyo kansarka unugyada unugyada ee madaxa iyo qoorta [SCCHN]) B) Adenocarcinoma iyo noocyada sanka, sanka, iyo nasopharynx (oo uxiran soo uruurinta 07/27/2018) 2. Burooyinka Epithelial ee qanjidhada waaweyn ee candhuufta (waxay uxiran yihiin kuleel 03 / 20/2018) 3. Burooyinka nooca qanjidhada candhuufta ee madaxa iyo qoorta, dibnaha, hunguriga, caloosha, neef mareenka iyo sambabka, naaska iyo meel kale (oo u xidhan ku uruursiga) 4. Kansarka aan kala sooca lahayn ee marinka caloosha iyo caloosha (GI) 5. Adenocarcinoma oo leh noocyo xiidmaha yar yar 05/10/2018) 6. Kansarka unugyada 'squamous cell carcinoma' oo leh noocyo kala duwan oo ah habka 'GI tract' (caloosha yar ee caloosha, xiidanka, malawadka, xammeetida) (oo u xiran isku soo uruurinta 10/17/2018) 7. Fibromixoma iyo adenocarcinoma mucinous fasal hoose ah (pseudomixoma peritonei) lifaaqa iyo ugxansidaha (uxiranyahay aruurinta 03/20/2018) 8. burooyinka qanjidhada oo dhif ah oo ay kujiraan kansarka unugyada 'acinar cell carcinoma', 'mucinous cystadenocarcinoma' ama 'serous cystadenocarcinoma'. Pancreatic adenocarcinoma uma qalmo 9. Intrahepatic cholangiocarcinoma (waxaa loo xiray aruurinta 03/20/2018) 10. Cudurka 'Extrahepatic cholangiocarcinoma' iyo xuubka dheecaanka 'bile duct' (waxaa loo xiray aruurinta 03/20/2018) 11. Kansarka Sarcomatoid ee sambabka 12. Bronchoalveolar carcinoma lung. Xaaladdaan waxaa sidoo kale loo yaqaan adenocarcinoma in situ, adenocarcinoma yar yar, lepidic adenocarcinoma lepidic, ama adenocarcinoma mucinous invasive 13. Burooyinka aan epithelial ee ugxan sidaha: A) Burooyinka unugyada jeermiska ee ugxansidaha B) Mullerian buro isku dhafan iyo adenosarcoma si loo ururiyo 03/30/2018) 14. Buro Trophoblastic: A) Choriocarcinoma (waxaa looxidhay isku xidhka 04/15/2019) 15. Carcinoma unugga ku-meelgaarka ah oo aan ka aheyn kan kalyaha, miskaha, kaadi mareenka, ama kaadiheysta (oo uxirmay aruurinta 04 / 15/2019) 16. Burada unugyada ee xiniinyaha iyo burooyinka jeermiska dheeriga ah: Burooyinka Apocrine / extramammary Cudurka Paget 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Kansarka xubinta taranka ilmo galeenka cad 43. Esthenioneuroblastoma 44. Kansarka Endometrial carcinosarcoma (burooyinka isku dhafan ee Mullerian isku dhafan) (waxaa loo xiray ku soo aruuritaan) 45. Unuga unugyada xubinta taranka ee unug cad kansarka ugxan sidaha 47. Cudurka caloosha ku dhaca ee caloosha ku dhaca (GTD) 48. kansarka xameetida 49. kansarka unugyada yar yar ee ugxansidaha, nooca hypercalcemic 50. burooyinka PD-L1 ee la kordhiyay 51. Angiosarcoma 52. Kaalinta weyn ee neuroendocrine carcinoma (burooyinka neuroendocrine pancreatic [PNET] waa inay lagu qoro Cohort 22; qanjirka 'prostate neuroendocrine carcinomas' waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) Cudurka kansarka xubinta taranka dumarka unugyada cad 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (burooyinka isku dhafan ee Mullerian ee isku dhafan) (oo uxirmay) 45. Kansarka xubinta taranka ilmagaleenka xubinta taranka oo cad 46. Cudurka kansarka ugxansidaha unugyada cad 47. Gestational trophoblastic disease (GTD) 48. Kansarka xameetida 49. Yaryar kansarka ugxansidaha ugxansidaha, nooca hypercalcemic ee 50. PD-L1 burooyinka la kordhiyay 51. Angiosarcoma 52. Carcinoma heer sare ah 'neuroendocrine carcinoma (burooyinka qanjidhka neuroendocrine [PNET] waa in lagu qoraa Kohort 22; qanjirka' prostate neuroendocrine carcinomas waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) Cudurka kansarka xubinta taranka dumarka unugyada cad 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (burooyinka isku dhafan ee Mullerian ee isku dhafan) (oo uxirmay) 45. Kansarka xubinta taranka ilmagaleenka xubinta taranka oo cad 46. Cudurka kansarka ugxansidaha unugyada cad 47. Gestational trophoblastic disease (GTD) 48. Kansarka xameetida 49. Yaryar kansarka ugxansidaha ugxansidaha, nooca hypercalcemic ee 50. PD-L1 burooyinka la kordhiyay 51. Angiosarcoma 52. Carcinoma heer sare ah 'neuroendocrine carcinoma (burooyinka qanjidhka neuroendocrine [PNET] waa in lagu qoraa Kohort 22; qanjirka' prostate neuroendocrine carcinomas waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) Cudurka kansarka ugxan sidaha 47. Gestational trophoblastic disease (GTD) 48. kansarka xameetida 49. kansarka unugyada yar yar ee ugxansidaha, nooca hypercalcemic 50. burooyinka PD-L1 ee la kordhiyay 51. Angiosarcoma 52. Cudurka 'neuroendocrine carcinoma' ee heer sare ah (burooyinka qanjidhka neuroendocrine [PNET) ] waa in lagu qoraa Cohort 22; qanjirka 'prostate neuroendocrine carcinomas' waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) Cudurka kansarka ugxan sidaha ee unugyada 47. Cudurka caloosha ku dhaca ee caloosha ku dhaca (GTD) 48. Kansarka xameetida 49. Kansarka yar yar ee ugxansidaha, nooca 'hypercalcemic type 50.' ] waa in lagu qoraa Cohort 22; qanjirka 'prostate neuroendocrine carcinomas' waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) qanjirka 'prostend neuroendocrine carcinomas' waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC) qanjirka 'prostend neuroendocrine carcinomas' waa in lagu qoraa Cohort 53). Kansarka sambabka unugyada yar xaq uma laha 53. Kansarka qanjirka 'prostate' ee unug-yar-yar ee neuroendocrine (t-SCNC)

Goobta: 878 goobood